Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Triplet therapy with venetocla...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Export Ready — 
Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Bibliographic Details
Main Authors: Abhishek Maiti, Courtney D. DiNardo, Naval G. Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Nicholas J. Short, Musa Yilmaz, Guillermo Montalban-Bravo, Alessandra Ferrajoli, Elias J. Jabbour, Nitin Jain, Maro Ohanian, Koichi Takahashi, Philip A. Thompson, Sanam Loghavi, Kathryn S. Montalbano, Sherry Pierce, William G. Wierda, Hagop M. Kantarjian, Marina Y. Konopleva
Format: Article
Language:English
Published: Nature Publishing Group 2021-02-01
Series:Blood Cancer Journal
Online Access:https://doi.org/10.1038/s41408-021-00410-w
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1038/s41408-021-00410-w

Similar Items

  • Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
    by: Musa Yilmaz, et al.
    Published: (2022-05-01)
  • S127: QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY
    by: M. Yilmaz, et al.
    Published: (2022-06-01)
  • Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
    by: Musa Yilmaz, et al.
    Published: (2020-10-01)
  • Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia
    by: Nicholas J. Short, et al.
    Published: (2019-02-01)
  • Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
    by: Musa Yilmaz, et al.
    Published: (2021-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs